如何在晚期前列腺癌中最优地排列可用的治疗线。
HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER.
机构信息
Division of Oncology and Radiotherapy, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Department of Clinical Oncology, School of Medicine University of Zagreb, Croatia.
出版信息
Acta Clin Croat. 2022 Oct;61(Suppl 3):32-44. doi: 10.20471/acc.2022.61.s3.5.
Abstract
Optimal sequencing of available therapy lines in patients with advanced prostate cancer often poses quite a challenge. The guidelines are sometimes equivocal and clinical trial data are not always applicable to a particular patient. There is a difference in availability of therapy options throughout the world. In decision making, a patient as a whole should be taken into consideration, not just the stage and biology of the disease, but also patient's age, performance status, comorbidities, previous therapy lines, drug's safety profile and patient's preferences. This review article will show certain therapeutic options in the treatment of advanced hormone-sensitive prostate cancer and castration resistant prostate cancer: non- metastatic and metastatic. An attempt will be made to clarify the optimal sequencing.
摘要
在晚期前列腺癌患者中，优化可用治疗线的序贯治疗常常是一个挑战。指南有时并不明确，临床试验数据并不总是适用于特定患者。世界各地的治疗选择的可用性存在差异。在决策中，不仅要考虑疾病的阶段和生物学特性，还要考虑患者的年龄、体能状态、合并症、既往治疗线、药物的安全性特征和患者的偏好，应将患者作为一个整体来考虑。本文将介绍晚期激素敏感型前列腺癌和去势抵抗性前列腺癌（非转移性和转移性）的某些治疗选择，并尝试阐明最佳的序贯治疗方案。
相似文献
1
HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER.如何在晚期前列腺癌中最优地排列可用的治疗线。
Acta Clin Croat. 2022 Oct;61(Suppl 3):32-44. doi: 10.20471/acc.2022.61.s3.5.
2
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
3
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分：晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
4
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.卡巴他赛对比阿比特龙或恩杂鲁胺治疗转移性前列腺癌患者的生活质量（CARD）：一项随机、多中心、开放性、4 期研究的分析。
Lancet Oncol. 2020 Nov;21(11):1513-1525. doi: 10.1016/S1470-2045(20)30449-6. Epub 2020 Sep 11.
5
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.CARD 研究：卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性去势抵抗性前列腺癌老年患者的疗效和安全性。
Eur Urol. 2021 Oct;80(4):497-506. doi: 10.1016/j.eururo.2021.06.021. Epub 2021 Jul 15.
6
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.紫杉烷类药物与新型激素药物阿比特龙和恩杂鲁胺之间的交叉耐药性可能会影响转移性去势抵抗性前列腺癌的药物序贯选择。
Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.
7
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.一线转移性去势抵抗性前列腺癌的治疗选择：CHAARTED 和 LATITUDE 时代的临床实践建议。
Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7.
8
Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.前列腺癌药物治疗：在 COVID-19 大流行期间临床医生错过了什么。
Am J Mens Health. 2022 Jul-Aug;16(4):15579883221115593. doi: 10.1177/15579883221115593.
9
Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.雄激素受体抑制剂在非转移性去势抵抗性前列腺癌中的安全性差异。
Future Oncol. 2023 Feb;19(5):385-395. doi: 10.2217/fon-2022-1123. Epub 2023 Feb 16.
10
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?我们对阿比特龙、恩杂鲁胺和化疗在转移性去势抵抗性前列腺癌中的治疗顺序了解多少？
World J Urol. 2016 May;34(5):617-24. doi: 10.1007/s00345-015-1687-0. Epub 2015 Sep 15.
引用本文的文献
1
Advanced single-cell and spatial analysis with high-multiplex characterization of circulating tumor cells and tumor tissue in prostate cancer: Unveiling resistance mechanisms with the CoDuCo in situ assay.前列腺癌中循环肿瘤细胞和肿瘤组织的高多重表征的先进单细胞和空间分析：通过CoDuCo原位检测揭示耐药机制。
Biomark Res. 2024 Nov 16;12(1):140. doi: 10.1186/s40364-024-00680-z.
2
The Complexity of Treatments and the Multidisciplinary Team-A Rare Case of Long-Term Progression-Free Survival in Prostate Cancer until Development of Liver and Brain Metastases.治疗的复杂性与多学科团队——前列腺癌长期无进展生存直至出现肝转移和脑转移的罕见病例
J Clin Med. 2023 Aug 27;12(17):5579. doi: 10.3390/jcm12175579.
3
Antitumor Effect of Açaí ( Mart.) Seed Extract in LNCaP Cells and in the Solid Ehrlich Carcinoma Model.阿萨伊（Mart.）种子提取物对LNCaP细胞和实体艾氏癌模型的抗肿瘤作用。
Cancers (Basel). 2023 Apr 28;15(9):2544. doi: 10.3390/cancers15092544.
本文引用的文献
1
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.一项关于转移性去势抵抗性前列腺癌患者恩扎卢胺的欧洲、前瞻性、观察性研究：PREMISE。
Int J Cancer. 2022 Mar 1;150(5):837-846. doi: 10.1002/ijc.33845. Epub 2021 Nov 8.
2
Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study.卡巴他赛治疗老年（≥75岁）去势抵抗性前列腺癌患者的疗效与安全性：一项多机构研究。
Prostate Int. 2021 Jun;9(2):96-100. doi: 10.1016/j.prnil.2020.12.001. Epub 2020 Dec 30.
3
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).2021年加拿大泌尿外科学会（CUA）-加拿大泌尿肿瘤学组（CUOG）指南：去势抵抗性前列腺癌（CRPC）的管理
Can Urol Assoc J. 2021 Feb;15(2):E81-E90. doi: 10.5489/cuaj.7074.
4
Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.转移性去势敏感前列腺癌的系统治疗比较：系统评价和网络荟萃分析。
JAMA Oncol. 2021 Mar 1;7(3):412-420. doi: 10.1001/jamaoncol.2020.6973.
5
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌诊治指南。第二部分-2020 年更新：复发性和转移性前列腺癌的治疗。
Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j.eururo.2020.09.046. Epub 2020 Oct 7.
6
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.恩扎卢胺治疗下非转移性去势抵抗性前列腺癌患者的前列腺特异性抗原进展：任何前列腺特异性抗原的升高都可能需要更密切的监测。
Eur Urol. 2020 Dec;78(6):847-853. doi: 10.1016/j.eururo.2020.08.025. Epub 2020 Oct 1.
7
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.前列腺癌：欧洲肿瘤内科学会临床实践指南之诊断、治疗及随访
Ann Oncol. 2020 Sep;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011. Epub 2020 Jun 25.
8
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.转移性去势抵抗性前列腺癌中恩扎卢胺和醋酸阿比特龙联合泼尼松序贯治疗的最佳顺序：一项多中心、随机、开放标签、2 期、交叉试验。
Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11.
9
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.非转移性去势抵抗性前列腺癌的治疗：聚焦阿帕鲁胺
Cancer Manag Res. 2019 Aug 1;11:7253-7262. doi: 10.2147/CMAR.S165706. eCollection 2019.
10
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.阿比特龙在“高-”和“低-”风险转移性激素敏感前列腺癌中的应用。
Eur Urol. 2019 Dec;76(6):719-728. doi: 10.1016/j.eururo.2019.08.006. Epub 2019 Aug 23.
Zotero 插件